Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT00410462 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT00410462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00410462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2006
Completion date
Not reported
Enrollment
118 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, sarcoma, small intestine cancer